已开发出一种铜 (II)/HOBt 催化合成二肽和“一般”酰胺的方法,使用微波辐射可显着加速反应。作为使用传统羧酸活化的替代方法,该方法依赖于使用 N-酰基咪唑作为活化的氨基伙伴。通过这样做,通过具有挑战性且研究较少的 N → C 方向合成,提出了一种非常规的方法来获得二肽和酰胺。已成功合成了一系列二肽和“通用”酰胺,并且该方法的适用性已在克级合成中得到说明。所提出的温和反应条件完全适合在敏感氨基酸存在下进行偶联,从而提供没有可检测到的外消旋作用的产物。此外,
Direct Synthesis of Amides from Carboxylic Acids and Amines Using B(OCH<sub>2</sub>CF<sub>3</sub>)<sub>3</sub>
作者:Rachel M. Lanigan、Pavel Starkov、Tom D. Sheppard
DOI:10.1021/jo400509n
日期:2013.5.3
range of amines. In most cases, the amide products can be purified by a simple filtration procedure using commercially available resins, with no need for aqueous workup or chromatography. The amidation of N-protected amino acids with both primary and secondary amines proceeds effectively, with very low levels of racemization. B(OCH2CF3)3 can also be used for the formylation of a range of amines in good
Hafnium-Catalyzed Direct Amide Formation at Room Temperature
作者:Helena Lundberg、Hans Adolfsson
DOI:10.1021/acscatal.5b00385
日期:2015.6.5
[Hf(Cp)2Cl2], as catalyst. Amino acids are transformed into their corresponding amides without racemization, and the catalyst displays full selectivity for the amidation of carboxylic acids overesters. Electronic properties of the carboxylic acids were found to have a strong influence on the rate of the amidation reaction, and the need for a balanced amount of molecularsieves was observed to be
A simple NaOMe catalyst provides superior accessibility to a wide variety of functionalized amides including peptides through direct amination of esters in an atom-economical and environmentally benign way.
[EN] NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES AMIDES HETEROCYCLIQUES UTILISES POUR LE TRAITEMENT D'AFFECTIONS INFLAMMATOIRES ET ALLERGIQUES; PROCEDE PERMETTANT DE LES FABRIQUER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
申请人:GLENMARK PHARMACEUTICALS LTD
公开号:WO2004022536A1
公开(公告)日:2004-03-18
The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE 4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes.
Design and Biological Activity of (<i>S</i>)-4-(5-{[1-(3-Chlorobenzyl)-2- oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-Aminopyrrolidinone Farnesyltransferase Inhibitor with Excellent Cell Potency
作者:Ian M. Bell、Steven N. Gallicchio、Marc Abrams、Douglas C. Beshore、Carolyn A. Buser、J. Christopher Culberson、Joseph Davide、Michelle Ellis-Hutchings、Christine Fernandes、Jackson B. Gibbs、Samuel L. Graham、George D. Hartman、David C. Heimbrook、Carl F. Homnick、Joel R. Huff、Kelem Kassahun、Kenneth S. Koblan、Nancy E. Kohl、Robert B. Lobell、Joseph J. Lynch、Patricia A. Miller、Charles A. Omer、A. David Rodrigues、Eileen S. Walsh、Theresa M. Williams
DOI:10.1021/jm010156p
日期:2001.8.1
The synthesis, structure-activity relationships, and biological properties of a novel series of imidazole-containing inhibitors of farnesyltransferase are described. Starting from a 3-amino-pyrrolidinone core, a systematic series of modifications provided 5h, a non-thiol, non-peptide farnesyltransferase inhibitor with excellent bioavailability in dogs. Compound 5h was found to have an unusually favorable ratio of cell potency to intrinsic potency, compared with other known FTIs. It exhibited excellent potency against a range of tumor cell lines in vitro and showed full efficacy in the K-rasB transgenic mouse model.